Guanidinoacetic Acid (GAA) Administration in Physically Active Men and Women
NCT ID: NCT01133899
Last Updated: 2011-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2010-03-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GAA-2
2.4 grams of guanidinoacetic acid
guanidinoacetic acid
2.4 grams of guanidinoacetic acid
GAA-1
1.2 grams of guanidinoacetic acid
GAA-1
1.2 grams of guanidinoacetic acid
GAA-4
4.8 grams of guanidinoacetic acid
GAA-4
4.8 grams of guanidinoacetic acid
PLACEBO
cellulose
PLACEBO
celulose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
guanidinoacetic acid
2.4 grams of guanidinoacetic acid
GAA-4
4.8 grams of guanidinoacetic acid
GAA-1
1.2 grams of guanidinoacetic acid
PLACEBO
celulose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 20 to 25 years
* experienced in athletic training
* free from musculoskeletal dysfunctions
* free from metabolic and heart diseases
* participating in consistent training (average of three times per week)
Exclusion Criteria
* pregnant women
* current intake of hormonal contraceptives
20 Years
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metropolitan University, Serbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sergej M. OSTOJIC
Heaf of Exercise Physiology Lab
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sergej M Ostojic, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Biomedical Sciences Dept, Faculty of Sport Sciences and Tourism, Metropolitan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biomedical Scinces Department, Exercise Physiology Lab
Novi Sad, Vojvodina, Serbia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Setoue M, Ohuchi S, Morita T, Sugiyama K. Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats. Biosci Biotechnol Biochem. 2008 Jul;72(7):1696-703. doi: 10.1271/bbb.70791. Epub 2008 Jul 7.
Ostojic SM. Creatine supplementation in young soccer players. Int J Sport Nutr Exerc Metab. 2004 Feb;14(1):95-103. doi: 10.1123/ijsnem.14.1.95.
BORSOOK ME, BORSOOK H. Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg. 1951 Oct;5(10):830-55. No abstract available.
da Silva RP, Nissim I, Brosnan ME, Brosnan JT. Creatine synthesis: hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo. Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E256-61. doi: 10.1152/ajpendo.90547.2008. Epub 2008 Nov 18.
Edison EE, Brosnan ME, Meyer C, Brosnan JT. Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. Am J Physiol Renal Physiol. 2007 Dec;293(6):F1799-804. doi: 10.1152/ajprenal.00356.2007. Epub 2007 Oct 10.
Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975 Jun;24(6):721-35. doi: 10.1016/0026-0495(75)90040-2.
Ostojic SM, Stojanovic M, Drid P, Hoffman JR. Dose-response effects of oral guanidinoacetic acid on serum creatine, homocysteine and B vitamins levels. Eur J Nutr. 2014 Dec;53(8):1637-43. doi: 10.1007/s00394-014-0669-0. Epub 2014 Feb 18.
Ostojic SM, Niess B, Stojanovic M, Obrenovic M. Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans. Int J Med Sci. 2013;10(2):141-7. doi: 10.7150/ijms.5125. Epub 2013 Jan 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AN-85E-S09
Identifier Type: -
Identifier Source: org_study_id